A Phase 2 Study to Explore the Dose of HCP1803 in Patients With Essential Hypertension

NCT04959305 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

245

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypertension

Interventions

DRUG: HCP1803-3
DRUG: RLD2003
DRUG: RLD2004
DRUG: RLD2005
DRUG: HPP2003-3
DRUG: HPP2005

Sponsor

Hanmi Pharmaceutical Company Limited